Innovassynth Technologies (India) Ltd
Incorporated in 2008, Innovassynth Technologies Ltd is a Contract Research, Development and Manufacturing Organization (CRDMO) specializing in pharmaceutical intermediates, oligonucleotide building blocks and specialty chemicals.
- Market Cap ₹ 626 Cr.
- Current Price ₹ 67.4
- High / Low ₹ 126 / 45.0
- Stock P/E
- Book Value ₹ 4.59
- Dividend Yield 0.00 %
- ROCE -0.99 %
- ROE -2.13 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 14.7 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.04% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -15 |
| OPM % | 22% | -39% | |||||||||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Profit before tax | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -24 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| -0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -23 | |
| EPS in Rs | -0.06 | -0.08 | -0.11 | -0.11 | -0.13 | -0.18 | -0.18 | -0.17 | -0.22 | -0.22 | -0.23 | -0.33 | -5.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -10% |
| TTM: | -353% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 54% |
| 3 Years: | 43% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 28 | 28 |
| Reserves | -1 | -1 | -1 | -2 | -2 | -4 | -4 | -4 | 11 | 10 | 9 | 15 | 15 |
| 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | |
| Total Liabilities | 24 | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 50 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 24 | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 50 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Assets | 24 | 24 | 24 | 24 | 24 | 23 | 23 | 23 | 39 | 39 | 39 | 50 | 50 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Net Cash Flow | 0 | -0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | 0 |
| Free Cash Flow | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1 |
| CFO/OP | 100% | 95% | 85% | 73% | 48% | 129% | 106% | 100% | 84% | 89% | 92% | 174% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | -1% | -1% | -1% | -1% | -1% | -2% | -2% | -1% | -1% | -1% | -1% | -1% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Turnover (Revenue) Rs. Crore |
|
||||||
| Capital Structure (Gearing Ratio) times |
|||||||
| Customer Concentration (Top Customer Revenue Share) % |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Consider And Approve Matters Relating To The Rights Issue Of The Company By The Rights Issue Committee.
2d - Rights Issue Committee meets on May 19, 2026 to consider allotment after issue closes May 18.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 May - Newspaper publication of the pre-issue advertisement of the rights issue.
-
Completion Of Dispatch Of Letter Of Offer Along With The Issue Material For Rights Issue.
4 May - Letter of Offer submitted for ₹69.64 crore rights issue of 1.74 crore shares at ₹40 each.
-
Revision In Outcome Of Rights Issue Committee Meeting Dated Thursday, April 23, 2026.
30 Apr - Rectified rights issue outcome: pre-issue shares 7.54 crore, post-issue 9.29 crore; no other changes.
-
Submission Of Letter Of Offer For Rights Issue Of Fully Paid-Up Equity Shares Of Innovassynth Technologies (India) Limited.
24 Apr - Letter of offer filed for 1.74 crore rights shares at ₹40, issue opens May 8, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
Business Overview:[1]
Innovassynth Technologies is a chemistry-focused CRDMO company engaged in research, development, and manufacturing across three key verticals — pharmaceutical intermediates, oligonucleotide building blocks, and specialty chemicals. It provides end-to-end services including custom synthesis, process development, scale-up, and commercial manufacturing for global life sciences and advanced materials customers. The company's oligonucleotide vertical focuses on nucleosides and amidites used in DNA/RNA therapeutics, while the specialty chemicals vertical serves applications in polyolefins, organometallic catalysts, and semiconductor materials. ITL uses chemistry capabilities, process innovation, and manufacturing expertise, to position itself as a long-term partner for global pharmaceutical and specialty chemical companies.